CClinicalTrials.gg
Status unknownNCT03870347Updated Mar 12, 2019

Opiate Use and Biliary Dilation

An observational study in Evaluation of Association Between Opiate Use and Biliary Dilation, sponsored by Stanford University. Status unknown at 1 site in United States. Per ClinicalTrials.gov, last updated 2019-03-12.

Sponsored by Stanford University · Observational

The sponsor has not verified this record recently (last verified Mar 2019), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Sex
All
01

Study summary

We hope to better define the association between opiate use and biliary dilation, which was evident in our previous retrospective study. This prospective study including all endoscopic ultrasound procedures performed for further evaluation of biliary dilatation in the setting of bilirubin \<2 mg/dL will enable accurate measurement of common bile duct and pancreatic duct diameter using endoscopic ultrasound and identification of other non- obstructive factors which may modulate biliary dilation (i.e. age, cholecystectomy status, duration and type of opiate used).

Read the detailed description

We hope to better define the association between opiate use and biliary dilation, which was evident in our previous retrospective study. This prospective study including all endoscopic ultrasound procedures performed for further evaluation of biliary dilatation in the setting of bilirubin \<2 mg/dL will enable accurate measurement of common bile duct and pancreatic duct diameter using endoscopic ultrasound and identification of other non- obstructive factors which may modulate biliary dilation (i.e. age, cholecystectomy status, duration and type of opiate used).

We believe this work will be of great interest to gastroenterologists, as it provides additional data for interpretation of isolated common bile duct dilation in asymptomatic patients.

02

Conditions studied

  • Evaluation of Association Between Opiate Use and Biliary Dilation
03

In context

Dilatation, Pathologic

260 studies on the registry are indexed under Dilatation, Pathologic; 43 are open to participants now.

This study's planned enrollment of 100 is close to the median of 94 across 64 observational studies indexed under Dilatation, Pathologic.

Browse Dilatation, Pathologic studies →

Lead sponsor

Stanford University is the lead sponsor of 2,117 studies on the registry; 425 are open to participants now.

Of its 259 completed or terminated interventional studies of FDA-regulated products, 197 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients referred for endoscopic ultrasound (EUS) or endoscopic retrograde cholangiopancreatography (ERCP) for further evaluation of abnormal imaging findings will be screened for inclusion in this study. Patients with biliary dilatation who meet all the inclusion criteria and have none of the exclusion criteria will be invited to participate in this prospective study during their initial clinic visit or hospital consultation.

Inclusion criteria

  1. Referral/consultation for consideration for EUS ± ERCP
  2. Age 18 and older
  3. Evidence of biliary dilation on abdominal imaging without obstructive pattern on liver function tests or imaging.
  4. Willing and able to comply with the study procedures and provide written informed consent to participate in the study.

Exclusion criteria

Exclusion Criteria:

  1. Age \<18
  2. Potentially vulnerable subjects including, homeless people, pregnant females, employees and students.
  3. Participation in another investigational study that may directly or indirectly affect the results of this study within 30 days prior to the initial visit
  4. Other biliary process which accounts for patient's abnormal liver function studies/imaging (i.e. mass, stone, cirrhosis).
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Biliary Dilation Cohort

    Patients referred for endoscopic evaluation of biliary dilation

    Diagnostic Test: Endoscopic ultrasound

Interventions

  • Diagnostic testEndoscopic ultrasound

    Upper endoscopy using an echoendoscope to obtain ultrasound images of the pancreaticobiliary system and adjacent structures.

06

What researchers measure

Primary outcomes

  1. Identification of factors associated with biliary dilation

    Statistical analysis will be conducted to assess for association between opiate use (including type and duration of opiates) and common bile duct diameter. We will also evaluate for other factors predictive of increased common bile duct diameter, which may include age and cholecystectomy status (based on our initial retrospective study). Power calculations to determine sample size were extrapolated from the initial retrospective study at our institution.

    Time frame: Up to 3 hours

  2. Identification of factors associated with pancreatic duct dilation

    Statistical analysis will be conducted to assess for association between opiate use (including type and duration of opiates) and common bile duct diameter. We will also evaluate for other factors predictive of increased common bile duct diameter, which may include age and cholecystectomy status (based on our initial retrospective study). Power calculations to determine sample size were extrapolated from the initial retrospective study at our institution.

    Time frame: Up to 3 hours

07

Study locations

1 of 1 sites recruiting
  • Stanford University Medical Center
    Stanford, California 94304, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 12, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03870347
Lead sponsor
Stanford University
Responsible party
Subhas Banerjee (Associate Professor of Medicine, Stanford University) — Principal investigator
First posted
Mar 12, 2019
Start date
Jan 3, 2018
Primary completion
Jan 2021 (estimated)
Completion
Jan 2022 (estimated)
Last update
Mar 12, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion